ABSTRACT
Background: Biological therapy has an important role in the treatment of Inflammatory Bowel Disease (IBD). However, the use of these drugs is resisted due to fears about their side effects. Aim: To report the experience with the use of Infliximab in patients with IBD. Material and Methods: Descriptive study of a historical cohort of patients with IBD treated between 2007 and 2012 with Infliximab. A favorable clinical response was considered when general, intestinal and extra-intestinal symptoms subsided after the second or third dose of the drug. Endoscopic or imaging response was evaluated between three and six months of treatment. Results: Twenty five patients aged 18 to 61 years (12 women) were included. Sixteen had Cohns Disease and 9 had Ulcerative Colitis. Treatment was indicated due to refractory disease in 13 patients, perianal involvement in nine, stenosis in two and pyoderma gangrenosum in one. Ten patients initiated Infliximab within less than two years of diagnosis. Twenty-two patients received combined treatment with immunosuppressive medications and the other three patients were treated exclusively with Infliximab. A favorable clinical response was observed in 88% after the second dose and 64% had endoscopic or imaging remission after 3-6 months. Twelve patients discontinued Infliximab, due to bad response to treatment in three patients, economic cost in three patients, and patient/doctor decision in six. Only three patients had side effects (herpes zoster and sinusitis). None of these motivated the discontinuation of treatment. Conclusions: In this cohort of patients with IBD, the use of Infliximab was associated with endoscopic or imaging remission in 64% of cases after 3-6 months of treatment with no major side effects.
Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Cohort Studies , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Remission Induction , Treatment OutcomeABSTRACT
Introducción: En la actualidad hay consenso en la seguridad oncológica en la cirugía laparoscópica para el tratamiento del cáncer de colon, sin embargo, en el cáncer de recto (CR) los resultados a largo plazo, continúan siendo objeto de estudio. El objetivo de este trabajo es analizar la sobrevida a largo plazo en pacientes operados por adenocarcinoma de recto por vía laparoscópica. Material y Métodos: Desde la base de datos prospectiva de cirugía colorrectal laparoscópica se seleccionaron los pacientes operados por CR en el periodo entre octubre 2000 y diciembre 2009. Se excluyó a los pacientes con cáncer colorrectal hereditario. Se analizaron los datos de seguimiento los cuales son obtenidos mediante registros clínicos y datos del registro civil. Se realizó un análisis de sobrevida con el método de Kaplan-Meier. Resultados: En el periodo mencionado, 60 pacientes fueron operados por CR, 2 (3,4%) pacientes fallecieron en el postoperatorio temprano y fueron excluidos en el análisis de sobrevida, por tanto, 58 pacientes fueron incluidos en el seguimiento. El 41% eran sexo femenino y la edad promedio fue de 60 ± 11,6 años. Los tumores se encontraban localizados en el recto superior, medio e inferior en un 28%, 28% y 44% respectivamente. Las cirugías realizadas fueron resección abdominoperineal, resección anterior ultrabaja interesfintérica, resección anterior ultrabaja y resección anterior baja en un 8%, 28%, 5% y 59% de los pacientes, respectivamente. El 50% de los pacientes recibieron neoadyuvancia. Tras la estadificación postoperatoria 4% fueron clasificados estadio 0, 38% estadio I, 17% estadio II, 28% estadio III y 13% estadio IV. El recuento de linfonodos de la pieza operatoria fue de 12,3 en promedio. A un seguimiento de 42,6 meses (r: 17 a 103 meses) la sobrevida global estimada a 5 años es de 85%. Según estadios la sobrevida estimada a 5 años fue de 100% para el estadio 0 y I, 88% para el estadio II, 74% para el estadio III... (TRUNCADO)
Background: Currently there is a consensus in oncological safety for laparoscopic surgery for colon cancer; however, in rectal cancer long term outcomes are still a subject of debate. The aim is to analyze long term survival in patients who underwent laparoscopic surgery for rectal cancer. Material and Methods: From the prospective database of laparoscopic colorectal surgery, we selected patients operated on between October 2000 and December 2009. Patients with hereditary colorectal cancer were excluded. Follow-up data was obtained by medical records and national vital records. Survival was analyzed using the Kaplan-Meier method. Results: In this period, 60 patients were operated on for rectal cancer. Two died in the early postoperative period and were excluded from the analysis; therefore, 58 patients were included in follow-up. Forty-one percent were female and mean age was 60±11.6 years old. Tumors were localized in the upper, mid and lower rectum in 28%, 28% and 44%, respectively. Surgeries performed were abdominoperineal resection, ultra-low intersphincteric resection, ultralow anterior resection and low anterior resection in 8%, 28%, 5% and 59% of patients, respectively. Fifty percent received neoadjuvant treatment. After postoperative staging 4% were classified as stage 0,17% as stage I, 28% as stage II, 28% as stage III, and 13% as stage IV. At a mean 42.6 month follow-up (r: 17-103 months) estimated overall 5-year survival was 85%. When analyzed according to stage, estimated overall 5-year survival was 100% for stages 0 and I, 88% for stage II, 74% for stage III, and 57% for stage IV. Conclusion: Long term survival in patients undergoing laparoscopic surgery for rectal cancer is satisfactory and is within the values reported by international centers.